NFA
PRTK

Nationwide Fund Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Nationwide Fund Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,355
Closed -$335K – 2347
2017
Q3 		$335K Hold
13,355
– – ﹤0.01% 2384
2017
Q2 		$322K Buy
13,355
+2,492
+23% +$55.1K ﹤0.01% 2410
2017
Q1 		$209K Sell
10,863
-922
-8% -$14.5K ﹤0.01% 2566
2016
Q4 		$181K Sell
11,785
-1,441
-11% -$18.7K ﹤0.01% 2652
2016
Q3 		$172K Buy
13,226
+4,302
+48% +$57K ﹤0.01% 2696
2016
Q2 		$124K Buy
8,924
+621
+7% +$9.14K ﹤0.01% 2833
2016
Q1 		$126K Buy
8,303
+501
+6% +$7.66K ﹤0.01% 2731
2015
Q4 		$148K Hold
7,802
– – ﹤0.01% 2694
2015
Q3 		$148K Sell
7,802
-103
-1% -$2.57K ﹤0.01% 2724
2015
Q2 		$204K Buy
7,905
+7,802
+7,575% +$221K ﹤0.01% 2699
2015
Q1 		$3K Hold
103
– – ﹤0.01% 3299
2014
Q4 		$4K Hold
103
– – ﹤0.01% 3205
2014
Q3 		$3K Hold
103
– – ﹤0.01% 3311
2014
Q2 		$2K Hold
103
– – ﹤0.01% 3299
2014
Q1 		$4K Hold
103
– – ﹤0.01% 3004
2013
Q4 		$4K Hold
103
– – ﹤0.01% 3220
2013
Q3 		$4K Sell
103
-472
-82% -$16.9K ﹤0.01% 3201
2013
Q2 		$21K Buy
+575
New +$24.6K ﹤0.01% 3081

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Nationwide Fund Advisors's PRTK Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 13,355 shares — an estimated $335K sold.

Nationwide Fund Advisors first reported a position in PRTK in Q2 2013 and held it in 18 quarters. The position peaked at $335K in Q3 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 13,355 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $335K.
  • Nationwide Fund Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Paratek Pharmaceuticals, Inc. position peaked at $335K in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.